医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

ニュース
添付文書
薬の臨床実感＆助言集

眼科医療

Sonoma Pharmaceuticals and Microderm Technologies Announce that Dermodacyn® Disinfecting Solution is Now Available in Hong Kong and Thailand

Sonoma Pharmaceuticals and Microderm Technologies Announce that Dermodacyn® Disinfecting Solution is Now Available in Hong Kong and Thailand

その他ヘルスヘルスケアヘルス一般マネージド・ケア医療用品医療管理外科感染症病院眼科医療　 TimeLine: Disinfecting Solution is Now Available in Hong Kong and Thailand Sonoma Pharmaceuticals and Microderm Technologies Announce that Dermodacyn

2021年01月29日

Korea’s KAHF-Designated Hospitals Taking the Lead in Protecting Rights and Interest of International Patients and Offering Quality Medical Services

Korea’s KAHF-Designated Hospitals Taking the Lead in Protecting Rights and Interest of International Patients and Offering Quality Medical Services

その他ヘルスヘルスケア外科病院眼科医療　 TimeLine: Korea’s KAHF-Designated Hospitals Taking the Lead in Protecting Rights and Interest of International Patients and Offering Quality Medical Services

2021年01月20日

Chugai’s Enspryng Approved in Taiwan as First Approved Medicine for Neuromyelitis Optica Spectrum Disorder (NMOSD)

Chugai’s Enspryng Approved in Taiwan as First Approved Medicine for Neuromyelitis Optica Spectrum Disorder (NMOSD)

バイオテクノロジーヘルスケア眼科医療臨床試験製薬　 TimeLine: Chugai’s Enspryng Approved in Taiwan as First Approved Medicine for Neuromyelitis Optica Spectrum Disorder NMOSD

2020年12月09日

Mojo Vision and Menicon Announce Joint Development Agreement on Smart Contact Lens Products

Mojo Vision and Menicon Announce Joint Development Agreement on Smart Contact Lens Products

ヘルスケアヘルス一般医療機器眼科医療　 TimeLine: Mojo Vision and Menicon Announce Joint Development Agreement on Smart Contact Lens Products

2020年12月09日

Kubota Vision Announces Submission of Novel VAP-1 Inhibitors to the NCI Developmental Therapeutics Program for Screening in Cancer Cell Lines

Kubota Vision Announces Submission of Novel VAP-1 Inhibitors to the NCI Developmental Therapeutics Program for Screening in Cancer Cell Lines

バイオテクノロジーヘルスケア眼科医療腫瘍学臨床試験製薬　 TimeLine: Kubota Vision Announces Submission of Novel VAP-1 Inhibitors to the NCI Developmental Therapeutics Program for Screening in Cancer Cell Lines

2020年12月08日

Azura Ophthalmics to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference

Azura Ophthalmics to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference

バイオテクノロジーヘルスケア眼科医療臨床試験　 TimeLine: 32nd Annual Virtual Healthcare Conference Azura Ophthalmics to Present at the Piper Sandler

2020年11月24日

NovaBay Pharmaceuticals Expands Avenova’s Geographic Reach to Australia with New Exclusive Distribution Agreement

NovaBay Pharmaceuticals Expands Avenova’s Geographic Reach to Australia with New Exclusive Distribution Agreement

バイオテクノロジーヘルスケア眼科医療製薬　 TimeLine: New Exclusive Distribution Agreement NovaBay Pharmaceuticals Expands Avenova’s Geographic Reach to Australia with

2020年11月23日

Ocular Therapeutix™ and AffaMed Therapeutics Announce License Agreement and Collaboration for DEXTENZA® and OTX-TIC in Asia

Ocular Therapeutix™ and AffaMed Therapeutics Announce License Agreement and Collaboration for DEXTENZA® and OTX-TIC in Asia

その他ヘルスバイオテクノロジーヘルスケアメンタルヘルス外科眼科医療臨床試験製薬　 TimeLine: and AffaMed Therapeutics Announce License Agreement and Collaboration for DEXTENZA and OTX-TIC in Asia Ocular Therapeutix

2020年10月30日

Santen and Aerie Conclude Exclusive License Agreement for Rhopressa® and Rocklatan® in Japan and Several Other Asian Countries

Santen and Aerie Conclude Exclusive License Agreement for Rhopressa® and Rocklatan® in Japan and Several Other Asian Countries

ヘルスケアヘルス一般眼科医療製薬遺伝学　 TimeLine: and Rocklatan in Japan and Several Other Asian Countries Santen and Aerie Conclude Exclusive License Agreement for Rhopressa

2020年10月28日

Azura Ophthalmics Raises US$20 Million for Registration Studies for Treatment of Leading Cause of Dry Eye Disease

Azura Ophthalmics Raises US$20 Million for Registration Studies for Treatment of Leading Cause of Dry Eye Disease

バイオテクノロジーヘルスケアヘルス一般病院眼科医療製薬　 TimeLine: Azura Ophthalmics Raises US$20 Million for Registration Studies for Treatment of Leading Cause of Dry Eye Disease

2020年10月22日